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Abstract
Background: The present study evaluated the expression of hepcidin mRNA in hepatocellular
carcinoma (HCC).
Methods: Samples of cancerous and non-cancerous liver tissue were taken from 40 patients with
HCC who underwent hepatectomy. Expression of hepcidin mRNA was evaluated by real-time
PCR, and compared in tumors differing in their degree of differentiation, number of tumors, and
vessel invasion. Correlations between hepcidin expression and the interval until HCC recurrence,
and the serum concentration of hepcidin were evaluated, together with the expression of mRNAs
for other iron metabolism molecules, ferroportin and transferrin receptor 2 (Trf2).
Results: Hepcidin mRNA expression in non-cancerous and cancerous tissues was 1891.8 (32.3–
23187.4) and 53.4 (1.9–3185.8), respectively (P < 0.0001). There were no significant differences in
hepcidin expression among tumors differing in their degree of differentiation, number of tumors,
or vessel invasion. There was no significant correlation between hepcidin expression and the
interval until HCC recurrence. The serum concentration of hepcidin-25 was not correlated with
hepcidin-mRNA expression. Finally, there were no significant differences in the expression of
mRNA for ferroportin and Trf2 between cancerous and non-cancerous tissues.
Conclusion: Expression of hepcidin mRNA is strikingly suppressed in cancerous, but not in non-
cancerous tissues, in patients with HCC, irrespective of ferroportin or Trf2 expression. Uniform
suppression of hepcidin may be linked to the development of HCC.
Background
Hepatocellular carcinoma (HCC) is a major cause of
death worldwide [1], and chronic inflammatory stress
caused by hepatitis viruses B and C plays a major role in
HCC carcinogenesis [2]. Furthermore, some studies have
indicated that iron overload is a major risk factor for
development of HCC [3]. Iron overload leads to the gen-
eration of reactive oxygen species (ROS), which cause
chronic inflammation in the liver [4]. Iron accumulation
is associated not only with the genetic iron overload dis-
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order, hemochromatosis, but also with acquired hemosi-
derosis after chronic viral hepatitis or in fatty liver [5-7].
Hepcidin is a key molecule for maintenance of iron home-
ostasis [8]. Hepcidin is produced in hepatocytes [9], and
binds to, internalizes, and degrades ferroportin-1 [10],
resulting in a decrease of serum iron concentration and an
increased intracellular iron content [11]. There is a consid-
erable body of evidence that expression of hepcidin is
altered in various types of diseases. Anemia of inflamma-
tion induces overexpression of hepcidin [12,13]. How-
ever, no studies have investigated the expression of
hepcidin in HCC.
In this study, we investigated the expression of hepcidin in
HCC and showed, for the first time, that it is strikingly
suppressed in this cancer.
Methods
Patients
Forty patients who had undergone hepatic resection and
had been diagnosed as having HCC by histological exam-
ination were included in the present study. The docu-
mented consent was obtained from the each patient. The
patients' background factors are summarized in Table 1.
The mean age was 62.1 ± 11.3 years, and there were 29
males and 11 females. The number of patients positive for
HCV, HBV, and both HCV and HBV was 11, 8, and 12,
respectively. Liver cirrhosis was observed in 22 patients
and chronic hepatitis was diagnosed in 15; only 3 patients
lacked chronic hepatitis or liver cirrhosis.
Real-time PCR
For real-time PCR, samples of both non-cancerous and
cancerous liver tissue were available for all 40 patients.
Surgical samples weighing 500 mg were stored in liquid
nitrogen immediately after the operation, and kept at -
80°C until RNA extraction. Total RNA from each sample
was isolated using a Total RNA Isolation Kit (Macherey-
Nagel, Düren, Germany). Reverse transcription reactions
were performed using a Rever Tra Ace α-First Strand cDNA
Synthesis Kit (Toyobo, Osaka, Japan). Briefly, 1 μg of total
RNA, oligo dT-primer, and dNTPs were incubated at 65°C
for 5 min, then 10 μL of a cDNA synthesis mixture was
added and the mixture was incubated at 50°C for 50 min.
The reaction was terminated by adding 1 μL of RNaseH
and incubating the mixture at 37°C for 20 min.
Real-time PCR was performed with an ABI Prism 7700
sequence detector (Applied Biosystems, Warrington, UK).
The PCR reaction was carried out in a final volume of 2 μL
cDNA, 12.5 μL 2 × SYBR Green (Applied Biosystems), 0.5
μL of 25 nM sense and antisense primers, and H2O up to
25 μL. The PCR conditions consisted of 40 cycles at 95°C
for 15 s and 60°C for 60 s. The sequences of the primers
were as follows: GAPDH: sense-primer 5'-CCACCCAGAA-
GACTGTGGAT-3', anti-sense 5'-TTCAGCTCAGGGAT-
GACCTT-3' ; hepcidin: sense-primer 5'-
CACAACAGACGGGACAACTT-3', anti-sense 5'-CGCAG-
CAGAAAATGCAGATG-3' [14]; ferroportin-1: sense-
primer 5'-CGAGATGGATGGGTCTCCTA-3', anti-sense 5'-
ACCACATTTTCGACGTAGCC-3' ; transferrin receptor-2
(Trf2): sense-primer 5'-CCTAGGCTCCCCTTATCACC-3',
anti-sense 5'-TCACCATGGAGGAAAAGGTC-3'.
The level of expression was calculated using the formula:
Relative expression (t) = (Copy number of target mole-
cule/Copy number of GAPDH) × 1000 [14]. Samples were
assayed in triplicate. Means and standard deviations were
calculated from the data obtained. For each sample, at
least three assays were performed. The t value was calcu-
lated from the mean of three different assays.
Disease-free survival and expression of hepcidin mRNA
For analysis of the correlation between hepcidin mRNA
expression and disease-free patient survival, 15 of the 40
patients who developed HCC recurrence within the study
period were included. As only 3 patients died of HCC in
the observation period, overall survival analysis was not
performed.
Table 1: 
Patients n = 40
Age (year) 62.1 ± 11.3
Sex
Male n = 29
Female n = 11
Virus
HCV+ n = 11
HBV+ n = 8
HCV+HBV+ n = 12
HCV-HBV- n = 9
Cirrhosis
Yes n = 22
No normal n = 3
CH n = 15
Tumor differentiation
Well n = 4
Moderately n = 32
Poorly n = 4
Number of tumors
1n  =  2 9
2n  =  5
3n  =  4
4- n = 2
Vessel invasion
Negative n = 31
Positive n = 9BMC Cancer 2008, 8:167 http://www.biomedcentral.com/1471-2407/8/167
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Measurement of serum hepcidin-25, iron, ferritin, and 
total iron binding capacity (TIBC)
Serum hepcidin-25, iron, ferritin, and TIBC were meas-
ured in blood samples collected from 15 patients with
HCC. Serum hepcidin-25 concentration was measured
using LC-MS/MS at Medical Care Proteomics Biotechnol-
ogy Co., Ltd. (Kanazawa, Japan). The measurement of
serum hepcidin-25 has been described elsewhere [15].
The normal serum hepcidin-25 level was 22.2 ± 12.3 ng/
mL. Analyses of the correlation between serum hepcidin
concentration and hepcidin mRNA expression were per-
formed using the serum samples and surgical specimens
from these 15 patients. Serum concentrations of iron, fer-
ritin, and TIBC were measured at BML, Inc. (Tokyo,
Japan). The normal serum levels of iron, ferritin, and TIBC
were determined according to the data from BML, Inc. The
normal serum iron values for men and women were set at
55–190 μg/dL and 45–145 μg/dL, respectively. The nor-
mal serum ferritin values for men and women were set at
20–250 ng/mL and 5–120 ng/mL, respectively. The nor-
mal TIBC values for men and women were set at 250–380
μg/dL and 250–450 μg/dL, respectively.
Statistical analyses
Comparisons between two groups were analyzed by
Mann-Whitney test (two-sided). One-factor ANOVA was
used for comparisons between more than 3 groups. Cor-
relations were analyzed using Spearman's correlation
coefficient by rank test. A probability value of P < 0.05 was
considered to indicate statistical significance.
Results
Hepcidin mRNA expression is suppressed in hepatocellular 
carcinoma
The median t values for hepcidin mRNA in non-cancerous
and cancerous tissues were 1891.8 (32.3–23187.4) and
53.4 (1.9–3185.8), respectively (P  < 0.0001) (Fig. 1).
Expression of hepcidin mRNA was significantly inhibited
in cancerous tissue.
Figure 2 shows the median t values for hepcidin mRNA in
cancerous tissues varying in their degree of tumor differ-
entiation, number of tumors, and vessel invasion. Median
t values for hepcidin mRNA in well, moderately and
poorly differentiated HCC were 355.9, 64.9, and 150.4,
respectively (P  = 0.999). Median t values for hepcidin
mRNA in patients who had 1, 2, 3 and 4 or more HCCs
were 71.5, 13.8, 79.2, and 144.0, respectively (P = 0.512).
Median t values for hepcidin mRNA in patients who were
negative and positive for vessel invasion were 68.8 and
53.4, respectively (P = 0.883).
Next, we investigated the correlation between the expres-
sion of hepcidin mRNA and patient disease-free survival
period (Fig. 3). There was no significant correlation
between the expression of hepcidin mRNA and disease-
free survival period (Fig. 3, r = 0.111, P = 0.693).
Figure 4 shows the expression of hepcidin mRNA in non-
cancerous tissue in patients with and without cirrhosis.
There was no significant difference in the expression of
hepcidin mRNA expression between the two groups (P =
0.170).
Ferroportin-1- and Trf2 mRNA expression is not 
suppressed in hepatocellular carcinoma
We also investigated the expression of mRNA for two
other molecules, ferroportin-1, and Trf2, which play a cru-
cial role in iron homeostasis (Fig. 5). Expression of ferro-
portin mRNA in non-cancerous and cancerous tissue was
37.9 (1.9–295.9) and 17.2 (2.6 – 794.9), respectively (P =
0.427), whereas that of Trf2-mRNA was 12.9 (5.2 – 54.8)
and 10.8 (0.2 – 67.2), respectively (P = 0.339).
Hepcidin mRNA expression is not correlated with serum 
hepcidin-25 concentration
We then investigated the serum concentration of bio-
chemical markers of iron metabolism. Among 15 patients
with HCC, the serum iron level was low in only 2 (52.3 ±
2.6 mg/mL), and normal in the other 13 (131.4 ± 23.4
mg/dL). The serum ferritin level was high in 4 patients
(414.4 (328.2–1121.0) ng/mL) and normal in 11 (179.5
(14.0–232.9) ng/mL). TIBC was low in 4 patients (194.0
± 14.1 ng/mL) and normal in 11 (284.8 ± 28.3 ng/mL).
The serum hepcidin-25 value was high in 5 patients (42.6
ng/mL (35.6–75.0)) and normal in 10 (15.5 ng/mL (1.2–
28.5)). There were significant correlations between the
serum levels of hepcidin-25 and iron (Fig. 6A, r = -0.756,
P = 0.007), hepcidin-25 and ferritin (Fig. 6B, r = 0.698, P
= 0.004), and hepcidin and TIBC (Fig. 6C, r = -0.652 P =
0.009).
The serum hepcidin-25 concentration was not signifi-
cantly correlated with expression of hepcidin mRNA in
non-cancerous tissue (Fig. 7A, r = 0.132, P = 0.638) or can-
cerous tissue (Fig. 7B, r = -0.407, P = 0.248).
Discussion
Hepcidin is a molecule playing a key role in iron homeos-
tasis. It is produced by the liver, and inhibits intestinal
iron absorption by enterocytes in the duodenum [16] and
also release of iron by macrophages and hepatocytes [17].
Production of hepcidin is controlled by various stimuli
and factors. Production of hepcidin is stimulated by iron
overload, inflammation, and proinflammatory cytokines
such as IL-6, whereas it is decreased by iron deficiency and
erythropoiesis, leading to iron accumulation in the body
[13].BMC Cancer 2008, 8:167 http://www.biomedcentral.com/1471-2407/8/167
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Suppression of hepcidin mRNA in cancerous tissue from patients with HCC Figure 1
Suppression of hepcidin mRNA in cancerous tissue from patients with HCC. (A) The median t values (horizontal 
bar) for hepcidin mRNA (n = 40) in non-cancerous and cancerous tissue were 1891.8 (32.3–23187.4) and 53.4 (1.9–3185.8), 
respectively (P < 0.05). α: statistically significant. (B) Representative results of real-time PCR of non-cancerous and cancerous 
tissue are shown.
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Hepcidin mRNA expression in tumors differing in their degree of differentiation, number of tumors, and vessel invasion Figure 2
Hepcidin mRNA expression in tumors differing in their degree of differentiation, number of tumors, and vessel 
invasion. Hepcidin mRNA expression did not differ among (A) well (n = 4), moderately (n = 32), and poorly (n = 4) differen-
tiated carcinoma, (B) patients with 1 (n = 29), 2 (n = 5), 3 (n = 4), and 4 or more (n = 2) HCCs, and (C) negative (n = 31) and 
positive (n = 9) for vessel invasion.
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Hepcidin mRNA expression in cirrhotic and non-cirrhotic  liver tissue Figure 4
Hepcidin mRNA expression in cirrhotic and non-cir-
rhotic liver tissue. Hepcidin mRNA expression in non-can-
cerous liver tissue did not differ between HCC patients with 
(LC, n = 22) and without (Non-LC, n = 18) cirrhosis.
LC Non-LC
0
5000
10000
15000
t
-
v
a
l
u
e
P= 0.170
Correlation between hepcidin mRNA expression and period  until HCC recurrence Figure 3
Correlation between hepcidin mRNA expression and 
period until HCC recurrence. Hepcidin mRNA expres-
sion (n = 15) was not correlated with the period until. HCC 
recurrence (r = 0.111, P = 0.693).
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Correlations between serum concentration of hepcidin and iron, ferritin, and TIBC Figure 6
Correlations between serum concentration of hepcidin and iron, ferritin, and TIBC. Serum concentration of hepci-
din (n = 15) was significantly correlated with serum concentration of iron (A), ferritin (B), and TIBC (C).
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Expression of mRNA for ferroportin-1 and Trf in HCC Figure 5
Expression of mRNA for ferroportin-1 and Trf in HCC. Expression of mRNA for ferroportin-1 (A) and Trf (B) did not 
differ between cancerous and non-cancerous tissue in patients with HCC.
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It is well known that HCC develops in more than 40% of
patients with hemochromatosis [18]. On the other hand,
iron is an essential nutrient for cell growth, and cancer
cells in particular require iron in order to proliferate [19].
The present study clearly demonstrated that expression of
hepcidin mRNA was suppressed universally in HCC, irre-
spective of the degree of tumor differentiation, and was
not correlated with the period until cancer recurrence.
Expression of hepcidin was maintained in non-cancerous
liver tissue of patients with HCC, and the level of hepcidin
expression did not differ between cirrhotic and non-cir-
rhotic liver (Figure 4). Although the mechanism reponsi-
ble for suppression of hepcidin mRNA expression in HCC
remains unclear, suppression of hepcidin transcription
contradicts the previously proposed scheme for iron
homeostasis in cancer cells, because cancer cells must
retain iron in order to proliferate. However, suppression
of hepcidin is rational because duodenal enterocytes
transfer iron to plasma, resulting in an increase of total
body iron content.
Recently, Weizer-Stern et al. reported that activation of the
tumor suppressor gene p53 stimulates the expression of
hepcidin [20]. The promoter region of the hepcidin gene
(HAMP) contains a putative p53 response element. Inac-
tivation or mutation of the p53 gene has been detected in
various types of human cancer [21], including HCC [22].
Suppression of hepcidin expression may be linked to the
altered expression and function of p53.
Ferroportin-1 is an iron transporter protein produced in
hepatocytes as well as duodenal enterocytes, macro-
phages, and placental cells [23]. Ferroportin-1 exports
iron from the intracellular to the extracellular space to
increase the iron content of plasma, and its expression is
regulated by intracellular iron content. Hepcidin binds to,
internalizes, and degrades ferroportin-1, resulting in an
increase of the intracellular iron content [24]. TfR2 is a
transmembrane type II protein expressed in the liver by
hepatocytes, and binds to transferrin [25]. It has been
reported that hepcidin expression is suppressed in TfR2
knockout mice, suggesting that TfR2 gene expression is
located upstream from hepcidin gene expression [26]. An
increase of TfR2 results in an increase of hepcidin produc-
tion. In the present study, expression of mRNA for ferro-
portin-1 and TfR2 did not differ between non-cancerous
and cancerous tissues, whereas the expression of hepcidin
was uniformly suppressed in cancerous tissues. The
expression of hepcidin was suppressed in HCC regardless
of the level of ferroportin-1 and TfR2 expression.
We found that serum hepcidin-25 concentration was cor-
related with the levels of serum iron and ferritin, but not
with the level of hepcidin mRNA expression in either can-
cerous or non-cancerous liver tissue (Figure 7). Hepcidin
is produced in patients with HCC, from non-cancerous
liver tissue, even though production is inhibited in cancer-
ous tissue.
Conclusion
Expression of hepcidin mRNA is constitutively suppressed
in cancerous, but not in non-cancerous liver tissue of
patients with HCC. The precise mechanism responsible
for the suppression of hepcidin in HCC should be investi-
gated further, focusing on its role in the development and
maintenance of this cancer.
Correlation between expression of hepcidin mRNA and serum concentration of hepcidin Figure 7
Correlation between expression of hepcidin mRNA and serum concentration of hepcidin. Expression of hepcidin 
mRNA was not correlated with serum concentration of hepcidin (n = 15) in non-cancerous or cancerous tissues.
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